Lu Gan

490 total citations
27 papers, 385 citations indexed

About

Lu Gan is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Lu Gan has authored 27 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Lu Gan's work include Cancer Immunotherapy and Biomarkers (9 papers), Immunotherapy and Immune Responses (5 papers) and CAR-T cell therapy research (3 papers). Lu Gan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Immunotherapy and Immune Responses (5 papers) and CAR-T cell therapy research (3 papers). Lu Gan collaborates with scholars based in United States, China and South Korea. Lu Gan's co-authors include Patrick Augustijns, R. Wayne Hendren, Dhiren R. Thakker, M. Arthur Moseley, David J. Greenblatt, Jerold S. Harmatz, Sachin N. Desai, Lauren A. Trepanier, Richard I. Shader and Jie Zhang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lu Gan

23 papers receiving 379 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lu Gan United States	9	229	93	87	71	64	27	385
Christopher Rowbottom United States	9	155 0.7×	95 1.0×	45 0.5×	61 0.9×	74 1.2×	9	346
Vishal S. Narang United States	8	182 0.8×	104 1.1×	47 0.5×	69 1.0×	31 0.5×	10	345
Lakshmi Vasist United States	11	185 0.8×	221 2.4×	55 0.6×	35 0.5×	20 0.3×	17	480
Ingrid Påhlman Sweden	11	152 0.7×	123 1.3×	73 0.8×	24 0.3×	30 0.5×	19	457
Machiel J. Hardonk Netherlands	13	143 0.6×	108 1.2×	89 1.0×	38 0.5×	52 0.8×	19	468
Phillip D. Gray United States	10	90 0.4×	110 1.2×	43 0.5×	94 1.3×	19 0.3×	13	353
Shubin Wang China	11	91 0.4×	153 1.6×	28 0.3×	12 0.2×	21 0.3×	21	399
Lingmin Yuan China	12	178 0.8×	319 3.4×	70 0.8×	39 0.5×	35 0.5×	20	453
Giancarlo Lunazzi Italy	11	180 0.8×	139 1.5×	29 0.3×	94 1.3×	11 0.2×	11	354
Magnus Ölander Sweden	8	70 0.3×	92 1.0×	25 0.3×	19 0.3×	15 0.2×	15	287

Countries citing papers authored by Lu Gan

Since Specialization

Citations

This map shows the geographic impact of Lu Gan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Gan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Gan more than expected).

Fields of papers citing papers by Lu Gan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lu Gan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Gan. The network helps show where Lu Gan may publish in the future.

Co-authorship network of co-authors of Lu Gan

This figure shows the co-authorship network connecting the top 25 collaborators of Lu Gan. A scholar is included among the top collaborators of Lu Gan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lu Gan. Lu Gan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zheng, Yurong, Xinyi Chen, Xinda Lin, et al.. (2025). DDX27: An RNA helicase regulating cancer progression and therapeutic prospects. International Journal of Biological Macromolecules. 313. 144388–144388.

Henry, Susan A., Stephen DeWall, Ulka N. Vaishampayan, et al.. (2023). 726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study. SHILAP Revista de lepidopterología. A821–A821. 1 indexed citations

Andtbacka, Robert H.I., Robert H. Pierce, Jean S. Campbell, et al.. (2022). Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma. Cancer Research Communications. 2(8). 904–913. 15 indexed citations

Shi, Haoze, Lu Gan, Ying Zhang, et al.. (2022). N6‐methyladenosine reader YTHDF3 regulates melanoma metastasis via its ‘executor' LOXL3. Clinical and Translational Medicine. 12(11). e1075–e1075. 22 indexed citations

Ren, Hui, et al.. (2021). Orbital exenteration for conjunctival melanoma: comparison of long-term outcome between individualised and conventional techniques. Eye. 35(12). 3410–3418. 4 indexed citations

Zhang, Zhikun, Qiaoying Chen, Tao Wu, et al.. (2021). Predicting the prognosis of liver cancer patients based on cell differentiation trajectory and application of nanomaterials in treatment. Minerva Surgery. 78(4). 441–444. 1 indexed citations

Choueiri, Toni K., Michael B. Atkins, Tracy L. Rose, et al.. (2021). A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. Investigational New Drugs. 39(4). 1019–1027. 34 indexed citations

Gan, Lu, Haoze Shi, Ying Zhang, Jianfang Sun, & Hao Chen. (2021). Proteomic Screening and Verification of Biomarkers in Different Stages of Mycosis Fungoides: A pilot Study. Frontiers in Cell and Developmental Biology. 9. 2 indexed citations

Yap, Timothy A., Minal Barve, Justin F. Gainor, et al.. (2021). First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.. Journal of Clinical Oncology. 39(15_suppl). TPS3146–TPS3146. 6 indexed citations

10.

Gan, Lu, et al.. (2020). Moxibustion for primary dysmenorrhea. Medicine. 99(1). e18547–e18547. 1 indexed citations

11.

Gan, Lu & Johanna C. Bendell. (2020). 402 DRAGON: Phase 1 trial of SRK-181, a latent TGFβ1 inhibitor in combination with anti-PD-(L)1 inhibitors for patients with solid tumors unresponsive to anti-PD-(L)1 therapy alone. SHILAP Revista de lepidopterología. A244.2–A245. 1 indexed citations

12.

Zhong, Liping, Lu Gan, Zhiming Deng, et al.. (2020). Antitumor Activity of Lipid-DNA Aptamer Modified T Lymphocytes in Carcinoma. Journal of Biomedical Nanotechnology. 16(7). 1110–1118. 8 indexed citations

13.

Badman, Michael K., Sachin N. Desai, Soniya Vaidya, et al.. (2019). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers. Clinical Pharmacology in Drug Development. 9(3). 395–410. 59 indexed citations

14.

Gan, Lu, et al.. (2018). Clinical and laboratory features of PCR-confirmed periocular tuberculosis in China. International Journal of Ophthalmology. 11(11). 1865–1869.

15.

Choueiri, Toni K., M.B. Atkins, Tracy L. Rose, et al.. (2018). A phase Ia/IIb trial of the CXCR4 inhibitor X4P-001 and nivolumab for advanced renal cell carcinoma (RCC) that is unresponsive to nivolumab monotherapy. Annals of Oncology. 29. viii402–viii403. 5 indexed citations

16.

Zhu, Xiaomei, Yang Li, Lu Gan, et al.. (2018). Oncogenomic analysis identifies novel biomarkers for tumor stage mycosis fungoides. Medicine. 97(21). e10871–e10871. 10 indexed citations

17.

Atkins, Michael B., Richard W. Joseph, Thai H. Ho, et al.. (2018). Abstract B201: A phase 1 dose-finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC). Molecular Cancer Therapeutics. 17(1_Supplement). B201–B201. 5 indexed citations

18.

Andtbacka, Robert H.I., Robert H. Pierce, Jean S. Campbell, et al.. (2018). Abstract 613: X4P-001, an orally bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma. Cancer Research. 78(13_Supplement). 613–613. 9 indexed citations

19.

Gan, Lu, Lisa L. von Moltke, Lauren A. Trepanier, et al.. (2008). Role of NADPH-Cytochrome P450 Reductase and Cytochrome-b5/NADH-b5 Reductase in Variability of CYP3A Activity in Human Liver Microsomes. Drug Metabolism and Disposition. 37(1). 90–96. 34 indexed citations

20.

Greenblatt, David J., Lu Gan, Jerold S. Harmatz, & Richard I. Shader. (2005). Pharmocokinetics and pharmacodynamics of single‐dose triazolam: electroencephalography compared with the Digit‐Symbol Substitution Test. British Journal of Clinical Pharmacology. 60(3). 244–248. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact